kpl-404
kpl-404: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Kiniksa Pharmaceuticals International, plc (KNSA)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | Phase 2 |
Clinical Trials (1)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
Frequently asked questions
Who is developing kpl-404?
kpl-404 is being developed by Kiniksa Pharmaceuticals International, plc.
How many clinical trials involve kpl-404?
BioSniper tracks 1 clinical trial involving kpl-404.
Analyze Kiniksa Pharmaceuticals International, plc & kpl-404 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company